BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1113 related articles for article (PubMed ID: 10914698)

  • 1. Temozolomide and treatment of malignant glioma.
    Friedman HS; Kerby T; Calvert H
    Clin Cancer Res; 2000 Jul; 6(7):2585-97. PubMed ID: 10914698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article.
    Koukourakis GV; Kouloulias V; Zacharias G; Papadimitriou C; Pantelakos P; Maravelis G; Fotineas A; Beli I; Chaldeopoulos D; Kouvaris J
    Molecules; 2009 Apr; 14(4):1561-77. PubMed ID: 19384285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temozolomide in malignant gliomas.
    Yung WK
    Semin Oncol; 2000 Jun; 27(3 Suppl 6):27-34. PubMed ID: 10866347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temozolomide: a milestone in neuro-oncology and beyond?
    Mutter N; Stupp R
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1187-204. PubMed ID: 16925485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis.
    Friedman HS
    Semin Oncol; 2000 Jun; 27(3 Suppl 6):35-40. PubMed ID: 10866348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
    Sipos L; Vitanovics D; Afra D
    Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Glioma therapy up-date].
    de la Fuente BP; Dalmau J; Rosenfeld M
    Neurologia; 2007 Apr; 22(3):159-69. PubMed ID: 17364254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide: a novel oral alkylating agent.
    Danson SJ; Middleton MR
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):13-9. PubMed ID: 12113120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme.
    Aoki T; Mizutani T; Ishikawa M; Sugiyama K; Hashimoto N
    Int J Clin Oncol; 2003 Oct; 8(5):301-4. PubMed ID: 14586755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prescription guidebook for temozolomide usage in brain tumors].
    Tilleul P; Brignone M; Hassani Y; Taillandier L; Taillibert S; Cartalat-Carel S; Borget I; Chinot O
    Bull Cancer; 2009 May; 96(5):579-89. PubMed ID: 19467988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
    Brada M; Judson I; Beale P; Moore S; Reidenberg P; Statkevich P; Dugan M; Batra V; Cutler D
    Br J Cancer; 1999 Nov; 81(6):1022-30. PubMed ID: 10576660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temozolomide chemotherapy in patients with recurrent malignant gliomas.
    Yang SH; Kim MK; Lee TK; Lee KS; Jeun SS; Park CK; Kang JK; Kim MC; Hong YK
    J Korean Med Sci; 2006 Aug; 21(4):739-44. PubMed ID: 16891823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
    Broniscer A; Chintagumpala M; Fouladi M; Krasin MJ; Kocak M; Bowers DC; Iacono LC; Merchant TE; Stewart CF; Houghton PJ; Kun LE; Ledet D; Gajjar A
    J Neurooncol; 2006 Feb; 76(3):313-9. PubMed ID: 16200343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temozolomide in malignant gliomas: current use and future targets.
    Villano JL; Seery TE; Bressler LR
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):647-55. PubMed ID: 19543728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temozolomide for recurrent high-grade glioma.
    Macdonald DR
    Semin Oncol; 2001 Aug; 28(4 Suppl 13):3-12. PubMed ID: 11550133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
    Jiang G; Wei ZP; Pei DS; Xin Y; Liu YQ; Zheng JN
    Biochem Biophys Res Commun; 2011 Mar; 406(3):311-4. PubMed ID: 21329652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of temozolomide using an extended continuous oral schedule.
    Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
    Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal role of temozolomide in the treatment of malignant gliomas.
    Stupp R; van den Bent MJ; Hegi ME
    Curr Neurol Neurosci Rep; 2005 May; 5(3):198-206. PubMed ID: 15865885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study.
    Trippoli S; Pelagotti F; Messori A; Vacca F; Vaiani M; Maltoni S
    Drugs R D; 2003; 4(5):285-91. PubMed ID: 12952497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
    Khan RB; Raizer JJ; Malkin MG; Bazylewicz KA; Abrey LE
    Neuro Oncol; 2002 Jan; 4(1):39-43. PubMed ID: 11772431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.